Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VAYA Pharma, a research-based, specialty pharmaceutical division of Enzymotec, has introduced Vayacog in the US for the management of early memory impairment in the elderly.
Subscribe to our email newsletter
Vayacog, a once-daily formulation of phosphatidylserine – omega 3 compound, DHA enriched, is a prescription medical food.
Regulated by the US Food and Drug Administration under the Orphan Drug Act, it is intended for the clinical dietary management of certain lipid imbalance associated with early memory impairment.
Vayacog has been clinically shown to safely improve short and long term memory abilities as well as learning skills.
Vayacog was evaluated during a 30-week, two-phase, clinical trial.
The first 15-weeks double-blind, randomized, placebo-controlled phase demonstrated significant differences between Vayacog and placebo groups in immediate and delayed memory recall and in total learning, specifically among participants with a relatively good cognitive performance prior treatment.
The double-blind phase was followed by an open-label extension of additional 15-weeks during which all participants received Vayacog.
Safety data, obtained during both the double-blind study and the open-label extension, showed that Vayacog was well tolerated with no significant side effects.
Vayacog is available in pharmacies throughout North Carolina, South Carolina and Texas.